Pivonello, C.
Patalano, R.
Simeoli, C.
Montò, T.
Negri, M.
Amatrudo, F.
Di Paola, N.
Larocca, A.
Crescenzo, E. M.
Pirchio, R.
Solari, D.
de Angelis, C.
Auriemma, R. S.
Cavallo, L. M.
Colao, A.
Pivonello, R. http://orcid.org/0000-0002-9632-1348
Funding for this research was provided by:
Ministero dell'Università e della Ricerca (PRIN 2015ZHKFTA)
Regione Campania (POR FESR CAMPANIA 2014 – 2020 RARE.PLAT.NET)
Università degli Studi di Napoli Federico II
Article History
Received: 23 May 2023
Accepted: 22 August 2023
First Online: 8 September 2023
Declarations
:
: R.P. has received research support to Università Federico II di Napoli as a principal investigator for clinical trials from Novartis Pharma, Recordati, Strongbridge Biopharma, Corcept Therapeutics, HRA Pharma, Shire, Takeda, Neurocrine Biosciences, Camurus AB, and Pfizer, has received research support to Università Federico II di Napoli from Pfizer, Ipsen, Novartis Pharma, Strongbridge Biopharma, Merk Serono, and Ibsa, and received occasional consulting honoraria from Novartis Pharma, Recordati, Strongbridge Biopharma, HRA Pharma, Crinetics Pharmaceuticals, Corcept Therapeutics, Pfizer, and Bresmed Health Solutions. A.C. has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk; consultant for Novartis, Ipsen, and Pfizer and received honoraria from Novartis, Ipsen and Pfizer. The remaining authors have nothing to disclose.
: The study was performed in accordance with the ethical standards of the Declaration of Helsinki, and it was approved by the Ethics Committee of the University Federico II of Naples (Italy) (EC Prot. 215/18). Healthy volunteers were recruited from staff and the University Federico II of Naples (Italy) faculty population. Healthy volunteers did not have any complaints regarding their health and did not have signs or symptoms indicative of CS after an endocrinological examination.
: All enrolled subjects provided signed informed consent.